UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Volltextzugriff (PDF)

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1694-1704

2018

Volltextzugriff (PDF)

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2308-2318

2020

Volltextzugriff (PDF)

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Clinical cancer research, 2012-04, Vol.18 (7), p.2099-2107

2012

Volltextzugriff (PDF)

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Molecular cancer research, 2020-09, Vol.18 (9), p.1278-1289

2020

Volltextzugriff (PDF)

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Clinical cancer research, 2016-03, Vol.22 (5), p.1197-1210

2016

Volltextzugriff (PDF)

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Pigment cell and melanoma research, 2016-11, Vol.29 (6), p.643-655

2016

Volltextzugriff (PDF)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003388

2021

Volltextzugriff (PDF)

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Molecular cancer research, 2017-08, Vol.15 (8), p.1096-1105

2017

Volltextzugriff (PDF)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

Cancer medicine (Malden, MA), 2023-02, Vol.12 (4), p.4236-4249

2023

Volltextzugriff (PDF)

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1514-e1525

2021

Volltextzugriff (PDF)

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Clinical cancer research, 2019-08, Vol.25 (16), p.4945-4954

2019

Volltextzugriff (PDF)

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Journal of clinical pharmacology, 2022-04, Vol.62 (4), p.532-540

2022

Volltextzugriff (PDF)

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma

Clinical cancer research, 2020-02, Vol.26 (4), p.828-836

2020

Volltextzugriff (PDF)

Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

British journal of clinical pharmacology, 2020-09, Vol.86 (9), p.1769-1777

2020

Volltextzugriff (PDF)

Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)

Neuro-oncology (Charlottesville, Va.), 2023-12, Vol.25 (12), p.2262-2272

2023

Volltextzugriff (PDF)

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

Cancer, 2020-11, Vol.126 (22), p.4936-4947

2020

Volltextzugriff (PDF)

In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation

Journal of clinical pharmacology, 2023-06, Vol.63 (6), p.672-680

2023

Volltextzugriff (PDF)

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Cancer, 2016-02, Vol.122 (4), p.588-597

2016

Volltextzugriff (PDF)

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Clinical cancer research, 2023-04, Vol.29 (8), p.1450-1459

2023

Volltextzugriff (PDF)

Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (6), p.1067-1082

2024

Volltextzugriff (PDF)

A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4), p.1076-1086

2021

Volltextzugriff (PDF)

Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model

Molecular cancer research, 2021-12, Vol.19 (12), p.2081-2095

2021

Volltextzugriff (PDF)

CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents

Cancer biology & therapy, 2011-03, Vol.11 (6), p.549-551

2011

Volltextzugriff (PDF)

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study

Clinical cancer research, 2014-11, Vol.20 (21), p.5392-5402

2014

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

KollektionIngenta.com

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Humans
(32)
Female
(21)
Male
(14)
Animals
(13)
Middle Aged
(13)
Pharmacokinetics
(13)
Adult
(10)
Aged
(10)
Mice
(9)
Neoplasms - Drug Therapy
(9)
Cancer
(8)
Immunotherapy
(7)
Treatment Outcome
(7)
Xenograft Model Antitumor Assays
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Patients
(6)
Toxicity
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma

Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer

A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models

Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model

CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study

Aktive Filter

Suchergebnisse filtern